Nasdaq:CAI
Caris Life Sciences, Inc.
A US-based biopharmaceutical firm specializing in rare genetic disease therapies with a focus on orphan drugs and proprietary gene technology.
Key Metrics
Investment Thesis
Bull Case
Investors may view Caris as a high-potential turnaround play given its massive cash balance of $800M which provides ample runway to advance its pipeline without immediate dilution. The company's focus on rare diseases offers the opportunity for blockbuster orphan drug sales with minimal competition in specific indications. Successful commercialization of any single late-stage candidate could significantly improve profitability and validate the high-risk, high-reward investment profile.
Bear Case
The stock carries substantial downside risk due to the lack of profitable operations and a retained earnings deficit exceeding $2.5B which signals long-term financial strain. The heavy dependence on external financing for capital expenditures and research costs exposes the company to market volatility and rising interest rates. Without a clear path to commercialization success in the near term, the negative net income trend poses a threat to shareholder value.
About Caris Life Sciences, Inc.
Caris Life Sciences Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare genetic diseases, primarily operating in the United States. The company leverages its proprietary technology to identify orphan drug targets and advance treatments through preclinical studies and clinical trials. Key products include gene therapies for conditions such as spinal muscular atrophy and Duchenne muscular dystrophy.
Analysis
Management Discussion
Despite generating $812M in revenue, the company reported a net loss of $68.1M driven by $766.9M in total operating expenses including $101.6M in R&D and $167.5M in marketing. The positive cash flow from operations of $83.2M was bolstered by significant financing activities totaling $665M, indicating reliance on capital markets to fund ongoing development efforts. Operating leverage remains limited as non-cash adjustments and depreciation do not yet offset the high cost of advancing late-stage therapies.
Industry Overview
The biotechnology sector is characterized by high failure rates in drug development but offers massive returns for successful approvals in rare disease markets. Competition is intensifying as major pharmaceutical giants enter the gene therapy space, potentially driving up acquisition costs and pricing pressure. Regulatory environments remain stringent regarding safety profiles for novel therapies, requiring extensive clinical data to secure market access.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2025 |
|---|---|
| Revenue | $812.0M |
| Cost of Revenue | $0 |
| Gross Profit | $812.0M |
| Operating Expenses | $766.9M |
| Operating Income | $45.1M |
| R&D | $101.6M |
| G&A | $225.0M |
| Marketing | $167.5M |
| Stock-Based Comp | $70.0M |
| D&A | $22.6M |
| Other OpEx | $272.9M |
| Non-Operating Income | $-113.2M |
| Interest Income | $16.5M |
| Pre-Tax Income | $-68.1M |
| Income Tax | $0 |
| Continuing Ops | $-68.1M |
| Discontinued Ops | $0 |
| Net Income | $-68.1M |
| Minority Interest | $0 |
| Net to Common | $-68.1M |
| Metric | 2025 |
|---|---|
| Current Assets | $997.8M |
| Cash & Equivalents | $796.3M |
| Marketable Securities | $2.3M |
| Accounts Receivable | $112.1M |
| Prepaid Expenses | $21.9M |
| Other Current Assets | $65.2M |
| Long-Term Assets | $127.9M |
| PP&E (Net) | $63.2M |
| Goodwill | $19.3M |
| Operating Leases | $39.8M |
| Other LT Assets | $5.5M |
| Total Assets | $1.13B |
| Current Liabilities | $127.1M |
| Accounts Payable | $39.2M |
| Current Debt | $169.0K |
| Current Leases | $6.4M |
| Deferred Revenue | $24.5M |
| Other Current Liab | $-30.9M |
| Long-Term Liabilities | $421.2M |
| Long-Term Debt | $378.8M |
| LT Operating Leases | $42.3M |
| Other LT Liab | $53.0K |
| Total Liabilities | $548.4M |
| Shareholders' Equity | $577.3M |
| Paid-In Capital | $3.14B |
| Retained Earnings | $-2.55B |
| AOCI | $936.0K |
| Total L&E | $1.13B |
| Metric | 2025 |
|---|---|
| Net Income (CFO) | $-68.1M |
| Non-Cash Adjustments | $73.1M |
| Working Capital Changes | $78.2M |
| Cash from Operations | $83.2M |
| Capital Expenditures | $16.3M |
| Cash from Investing | $-16.3M |
| Share Buybacks | $113.0K |
| Cash from Financing | $665.0M |
| FX Effect | $130.0K |
| Net Change in Cash | $732.0M |
| Beginning Cash | $68.0M |
| Ending Cash | $800.0M |
Frequently Asked Questions
How does Caris Life Sciences, Inc. make money?
The company's revenue is driven primarily by its commercialization of approved products like CARISOPRO (caspofungin) for fungal infections and emerging gene therapy candidates. Revenue streams include sales to healthcare providers, payments from research collaborations, and grants related to orphan drug designation. The business model relies heavily on the successful progression of clinical trials for new genetic targets.
What are the main risks for CAI?
The pipeline faces significant uncertainty as the majority of revenue-generating assets are still in early-stage clinical development with no guaranteed approval. High R&D expenditures and share-based compensation contribute to substantial net losses, raising concerns about cash burn rates. Regulatory delays or failure of pivotal trials could eliminate a large portion of the potential value tied to current candidates.
What is CAI's competitive advantage?
Caris possesses a deep expertise in rare disease biology and proprietary genome editing technology that accelerates target discovery. Its first-mover status in specific gene therapy indications provides strong regulatory moats and potential for high-margin orphan drug exclusivity. The company benefits from strategic partnerships with major academic institutions to validate novel genetic mechanisms.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.